Photo via CBS News

Her son was dying, but his rare cancer made it difficult to get the right drug

Read the original at CBS News ↗
Cite

Allen, A. (2026, September 21). Her son was dying, but his rare cancer made it difficult to get the right drug. CBS News. https://www.cbsnews.com/news/rare-cancer-drugs-insurance/

Dated when The Aporia collected the article, usually within hours of publication. Check the original for its exact date and byline.

CBS News · collected 2026-09-21 · by Arthur Allen

Quick Summary

Mason Henderson, diagnosed with a rare brain tumor in Texas two years ago, faced insurmountable challenges as his condition worsened despite conventional treatments and participation in clinical trials. His doctors recommended an unapproved drug, Lynparza, based on genetic analysis of his tumor, but his insurance company denied coverage due to lack of FDA approval for this specific use. This case highlights the difficulties rare cancer patients face when seeking innovative treatment options not covered by standard guidelines or insurance policies.
Written by AI on 2026-09-21, from this article's own text only (the story summary below draws on all the coverage).

AI analysis

Story summary

Mason Henderson, a 21-year-old from southeastern Texas, was diagnosed with a rare brain tumor in late 2020. Despite undergoing chemotherapy and participating in a clinical trial in New York City, his condition worsened as the cancer spread to his spinal fluid. His doctors then recommended the drug Lynparza by Merck and AstraZeneca, but since Henderson's insurance did not cover it due to its non-standard status for his specific type of cancer, obtaining the treatment became challenging. In March, Tabitha Lowe, Henderson’s mother, expressed frustration with her son's insurance company, stating they were discriminating against him because his cancer was rare. Approximately one-quarter of U.S. cancers are categorized as rare, highlighting the difficulties in securing appropriate treatments for such cases.

Written for “Child Cancer Treatment Struggle” on 2026-11-03, grounded in this article and the 0 other(s) covering the same event.

Story

📰 Child Cancer Treatment Struggle
Health · 1 article(s) covering the same event.

Compared with similar articles

Nothing to compare against. No article is close enough to this one for the pipeline to have linked or judged the pair.
How this article was measured signals, leaning charts, publisher record, byline, topics and claims

Signals How these are calculated →

Claims extracted
101
sentences that state something as happening or true
Uncertain
5%
5 of 101 hedged ("reportedly", "may", "according to")
Leaning
withheld
no quote in the article backed the model's score
Publisher signals
66/100
CBS News's corrections and hedging, across everything collected from it. Not a measure of accuracy.
Outlets on this story
1
Health
Same framing elsewhere
1
articles that frame the event the way this one does
Analyzed 2026-09-21 · how these are computed

How this is being covered How these are calculated →

Article leaning vs. publisher reliability
Source leaning vs. consistency

Publisher

CBS News · 4473 article(s) · 6 correction(s) detected
Running correction rate · 6 correction(s)

Who wrote this

Arthur Allen
1 article(s) here · 1 carrying a prediction
🔮 And Henderson's insurance would not pay for it, despite the careful justification given by the two specialists treating him.
The only article under this byline in the corpus.

Topics

Henderson Liviniti Lynparza New York City Texas

Subjects

Henderson GPE · 14× Lowe PERSON · 3× Schulte PERSON · 3× Beaumont GPE · 2× Liviniti ORG · 2× Texas GPE · 2× Mason Henderson PERSON · 1× Merck ORG · 1× New York City GPE · 1× the World Health Organization ORG · 1×

Narrative

"I was forced to become a PBM, insurer, research expert, all while trying to be his mother." KFF Health News is a national newsroom that produces in-depth journalism about health issues and is one of the core operating programs at KFF — the independent source for health policy research, polling, and journalism.
framing: assertive · carried by 1 article(s) · first seen 2026-09-21
🔮 And Henderson's insurance would not pay for it, despite the careful justification given by the two specialists treating him.

Claims (101 extracted, 5 hedged)

Eighteen months after his initial diagnosis, chemotherapy hadn't slowed 21-year-old Mason Henderson's rare brain tumor, which had spread to his spinal fluid. asserted
which → slow → fluid
So he left his home in southeastern Texas to spend three weeks in a clinical trial in New York City. asserted
he → leave → City
But that failed, too, leaving a murky path for Henderson, whose cancer was so rare the World Health Organization had only given it a name in 2021. asserted
Organization → fail → 2021
So early this year, Henderson's doctors, evaluating his tumor's deep genetic language, turned to a drug made by Merck and AstraZeneca called Lynparza. asserted
doctors → evaluate → Merck
It was not the standard of care for Henderson's condition — there wasn't really any standard, which is not unusual for rare cancers. asserted
which → be → cancers
And Henderson's insurance would not pay for it, despite the careful justification given by the two specialists treating him. asserted
insurance → pay → him
"They have no guidelines for his cancer," Henderson's mother, Tabitha Lowe, said in a March interview with KFF Health News. asserted
mother → have → News
"They're discriminating against him because his cancer is so rare." asserted
cancer → discriminate → him
Every year, tens of thousands of people — representing about a quarter of all U.S. cancers — are diagnosed with tumors that differ enough from frequently identified ones to be called rare. asserted
that → represent → ones
In determining whether to reimburse treatment for such ailments, insurers turn to Food and Drug Administration labels and expert guidelines. asserted
insurers → determine → labels
But these rare afflictions often lack targeted, FDA-approved treatment options, even though in many cases, molecular tests offered by diagnostic companies and university labs can provide a strong suggestion of what will work. asserted
what → lack → suggestion
"Insurance coverage routinely trails behind what genomic testing reveals about a patient's cancer and what the science supports," said Olivier Elemento, director of Weill Cornell Medicine's Englander Institute for Precision Medicine. asserted
Elemento → trail → Medicine
Henderson's neuro-oncologists, Jacob Mandel of the Baylor College of Medicine and Jessica Schulte of NYU Langone Health, decided to try Lynparza, also known by the generic name olaparib, in combination with chemotherapy. asserted
oncologists → decide → chemotherapy
There wasn't a wealth of evidence behind the drug but there was a "biologically reasonable" assumption it would help, Schulte said, because cells in tumors like Henderson's have a flaw that drugs like Lynparza can target. asserted
drugs → be → Lynparza
Providers in several previous cases had seen brain cancers like Henderson's respond well to the drug. asserted
cancers → see → drug
"In general, we try to base our treatment decisions on large patient studies" involving hundreds of patients, Schulte said. asserted
Schulte → try → patients
But large clinical trials will probably never be conducted for a cancer as rare as Henderson's asserted
trials → conduct → Henderson
Schulte, who specializes in brain cancers in young adults, sees only a few of Henderson's type each year, she said. asserted
she → specialize → type
Mandel prescribed the drug on Jan. 16. asserted
Mandel → prescribe → Jan.
Liviniti, Henderson's pharmacy benefit manager, responded with a quick refusal on Jan. 30. asserted
Liviniti → respond → Jan.
Two weeks later, the company sent an explanation: "Lynparza is not approved for the diagnosis provided." asserted
Lynparza → send → diagnosis
Out-of-pocket, the drug would cost about $8,700 per month, Lowe said. asserted
Lowe → cost → month
Liviniti did not respond to phone calls seeking comment. asserted
Liviniti → respond → comment
Before his diagnosis, Henderson was a healthy, athletic young man with a big heart, faith in Jesus, and a tight group of friends, his mother said. asserted
mother → say → friends
At Evadale High School, north of Beaumont, Texas, Henderson played baseball and football and was homecoming king in 2022. asserted
Henderson → play → 2022
After graduating, he worked at the local paper mill, spending his free time hunting, fishing, and exploring the woods on an all-terrain vehicle. asserted
he → graduate → vehicle
He wanted to be a police officer, Lowe said. asserted
Lowe → want → ?
Henderson was 20 on March 15, 2024, when his brother Gunner found him at the top of the stairs in the family home with his head in his hands. asserted
brother → find → hands
"He was in the post-seizure state," Lowe said. asserted
Lowe → say → state
"He couldn't talk. asserted
He → talk → ?
At an emergency room in Beaumont, an MRI revealed a large tumor. asserted
MRI → reveal → tumor
He was transferred to Baylor St. Luke's Medical Center in Houston and diagnosed with a form of brain cancer called diffuse hemispheric glioma (H3 G34-mutant). asserted
He → transfer → cancer
Surgery a few days later cut out 90% of the tumor, but brain cancers are almost impossible to remove entirely, because of the delicacy of the tissue they're embedded in, Schulte said. asserted
Schulte → cut → tissue
After 16 months of radiation and chemotherapy, a September 2025 scan showed the cancer had spread to his spinal cord, a condition called leptomeningeal disease that usually proves fatal within a few months. asserted
that → show → months
Mandel contacted Schulte about a clinical trial she was leading. asserted
she → contact → trial
It consisted of 11 days of brutal craniospinal irradiation, which left Henderson exhausted. asserted
which → consist → Henderson
"The family was wonderful," Schulte recalled. asserted
Schulte → recall → ?
"They were trusting in their team, but they asked appropriate questions to make sure that we were thinking about Mason as a person. asserted
thinking → trust → person
Coverage refused Lynparza, approved by the FDA in 2014 for ovarian cancer, works by interfering with tumor cells' ability to multiply. asserted
works → refuse → ability
After Liviniti, the pharmacy benefit manager, refused coverage for Henderson, his family turned to Jefferson County. asserted
family → refuse → County
…and 61 more, not listed.
💬Give feedback
🕘History 🎫Support